NZ741667A - Prostate-associated antigens and vaccine-based immunotherapy regimens - Google Patents

Prostate-associated antigens and vaccine-based immunotherapy regimens

Info

Publication number
NZ741667A
NZ741667A NZ74166713A NZ74166713A NZ741667A NZ 741667 A NZ741667 A NZ 741667A NZ 74166713 A NZ74166713 A NZ 74166713A NZ 74166713 A NZ74166713 A NZ 74166713A NZ 741667 A NZ741667 A NZ 741667A
Authority
NZ
New Zealand
Prior art keywords
vaccine
immunogenic
antigen
nucleic acid
polypeptides
Prior art date
Application number
NZ74166713A
Inventor
Joseph John Binder
Helen Kim Cho
Michael Robert Dermyer
Karin Ute Jooss
Brian Gregory Pierce
Joyce Tsi Tan
Van To Tsai
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NZ741667A publication Critical patent/NZ741667A/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer. The claimed invention relates to dual-antigen constructs encoding two of PSA, PSCA, and PSMA, characterised by the PSA antigen being an immunogenic cytosolic PSA antigen sequence and/or the PSMA antigen being an immunogenic truncated membrane bound PSMA antigen sequence.
NZ74166713A 2012-05-04 2013-04-29 Prostate-associated antigens and vaccine-based immunotherapy regimens NZ741667A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642844P 2012-05-04 2012-05-04
NZ71949913 2013-04-29

Publications (1)

Publication Number Publication Date
NZ741667A true NZ741667A (en) 2019-11-29

Family

ID=68652888

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ74174213A NZ741742A (en) 2012-05-04 2013-04-29 Prostate-associated antigens and vaccine-based immunotherapy regimens
NZ74166713A NZ741667A (en) 2012-05-04 2013-04-29 Prostate-associated antigens and vaccine-based immunotherapy regimens

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ74174213A NZ741742A (en) 2012-05-04 2013-04-29 Prostate-associated antigens and vaccine-based immunotherapy regimens

Country Status (1)

Country Link
NZ (2) NZ741742A (en)

Also Published As

Publication number Publication date
NZ741742A (en) 2019-11-29

Similar Documents

Publication Publication Date Title
PH12014502438A1 (en) Prostate-associated antigens and vaccine-based immunotherapy regimens
CY1121934T1 (en) ANTI-FCRN ANTIBODIES
CA2817709C (en) Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
CY1125392T1 (en) COMPOSITIONS AND METHODS OF PROTEINS
MX2015008446A (en) Multivalent binding protein compositions.
BR112013005699A2 (en) 4-1bb binding molecules
MX2019007921A (en) Novel ha binding agents.
DK2681244T3 (en) CEA ANTIBODIES
MX352974B (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof.
MX2018008135A (en) Influenza nucleic acid molecules and vaccines made therefrom.
MX2013007904A (en) Anti-il-12/il-23 antibodies and uses thereof.
EA201990114A1 (en) PR13.5 PROMOTOR FOR SUSTAINABLE T-CELL AND HUMORAL IMMUNE REACTIONS
EA201300896A1 (en) MUTANT POLYPEPTIDES OF INTERLEUKIN-2
WO2012018907A3 (en) Polypeptides for treating and/or limiting influenza infection
WO2014151834A3 (en) Methods and compositions relating to anti-ccr7 antigen binding proteins
BR112018073660A2 (en) anti-factor ix padua antibodies
WO2013138259A3 (en) Polypeptides for treating and/or limiting influenza infection
PH12018501532A1 (en) Cancer vaccines
NZ741667A (en) Prostate-associated antigens and vaccine-based immunotherapy regimens
WO2013093514A3 (en) Vaccines - peptides
WO2012076157A3 (en) Malaria vaccines based on pre-erythrocytic antigens from p. falciparum

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 APR 2021 BY AJ PARK

Effective date: 20200327

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 APR 2022 BY THOMSON REUTERS

Effective date: 20210313

LAPS Patent lapsed